What smart money is saying about Bio-Techne
3 funds in our archive have pitched Bio-Techne, most recently Clearbridge Mid Cap Strategy in September 2025.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
12 lettersMore funds are selling than buying
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q1 2025 and Q3 2026, 17 fund letters reported a position in Bio-Techne, with 3 buys (opened or added) and 7 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 7 | 1 | 5 | 0 |
| Q2 2026 | 5 | 1 | 2 | 0 |
| Q3 2025 | 2 | 1 | 0 | 1 |
| Q2 2025 | 3 | 0 | 0 | 1 |
| Q1 2025 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 17 positions · 11 moves
- September 2026
“Highlights include: • Affirm, in the financials sector, is a leading “buy now, pay later” platform offering consumers installment financing at checkout and through its own Affirm Card. We believe its underwriting capabilities, high-profile merchant partnerships and fast-growing card business position it to keep gaining share of consumer payments while expanding profitability. • Kiniksa Pharmaceuticals, in the health care sector, is a commercial- stage biotechnology company focused on pericarditis, an inflammatory heart disease. We believe that its ARCALYST drug, the only approved treatment for recurring and painful inflammation of the lining around the heart, still has a long growth runway, while a follow-on drug in late-stage trials could extend the drug franchise with better economics. • Timken, in the industrials sector, is a global leader in engineered bearings and industrial motion products. We believe the company is well positioned for a recovery in short-cycle industrial demand, while new management’s portfolio reshaping and streamlining efforts should drive meaningful margin expansion and earnings growth. • During the quarter we exited life sciences tools provider Bio-Techne following its announced acquisition by Merck KGaA.”
Bio-Techne - September 2026
“2Q 2024 Commentary 5 | Aristotle Atlantic Partners, LLC Quarterly Commentary – Large Cap Growth Sells Bio-Techne We sold Bio-Techne following the announcement of Merck KGaA’s agreement to acquire the company for $73 per share in cash.”
Bio-Techne - September 2026
“1. Bio-Techne Corp. (TECH) TECH provides life sciences research tools and diagnostic products to biopharmaceutical, academic and clinical customers. We exited the position following the company’s agreement to be acquired by Merck KGaA for $73 per share in cash, representing an enterprise value of approximately $11.3 billion.”
Bio-Techne - September 2026
“Bio-Techne Corporation (TECH): TECH is a global life science company providing tools and bioactive reagents for research and clinical diagnostic companies. Based in Minneapolis, TECH recently announced that Merck KGaA (MRK) has agreed to acquire Bio-Techne in an all-cash transaction valued at approximately $11.3 billion. Shareholders will receive $73 per share. After a full review of this transaction and an analysis of its risk reward versus the market set of opportunities, we have entered into a position.”
Bio-Techne - September 2026
“1. Bio-Techne Corp. (TECH) TECH provides life sciences research tools and diagnostic products to biopharmaceutical, academic and clinical customers. We exited the position following the company’s agreement to be acquired by Merck KGaA for $73 per share in cash, representing an enterprise value of approximately $11.3 billion.”
Bio-Techne - September 2026
“We sold most of the Fund’s Bio-Techne stock as it traded near the $73 takeout price offered by Merck KGaA.”
Bio-Techne - September 2026
“We sold most of the Fund’s Bio-Techne stock as it traded near the $73 takeout price offered by Merck KGaA, and we trimmed a handful of other stock positions to balance sizing, valuation, and conviction.”
Bio-Techne - June 2026
“During the quarter, we added modestly to our investments in Bio-Techne, SAP, and ICON Plc, and initiated a new position”
Bio-Techne - June 2026
“We reallocated capital away from several top contributors (Alphabet, Analog Devices, Bio- Techne) to manage position sizes at higher, less attractive prices.”
Bio-Techne - June 2026
“Notable 2Q Contributors Texas Instruments and Analog Devices were the Fund’s top contributors in the quarter. Recent results have been very strong, and sentiment has been even better, with power management solutions driving the latest leg in the analog semiconductor rally. Bio-Techne’s stock rose 35% as the company agreed to be acquired by Merck KGaA of Darmstadt, Germany, in late June.”
Bio-Techne - June 2026
“Portfolio activity beyond the entries and exits above was more muted and tilted toward trims. Beyond the exits of Accenture and Salesforce, we also trimmed our holdings of Alphabet, Amazon, Bio-Techne, SiriusXM and Thermo Fisher, partially offset by additions to Danaher and Global Payments.”
Bio-Techne “5. Bio-Techne Corp. (TECH) TECH develops life science research tools, and diagnostic products used by pharmaceutical, biotechnology, and academic researchers.”
Bio-Techne- September 2025
“BioTechne (TECH), which makes high quality ingredients for biopharmaceutical research and production, underperformed due to uncertainty around the funding environment for biopharmaceuticals and biotech research given recent federal funding cuts and a weak venture capital funding environment. We have taken advantage of the recent weakness to add to our Bio-Techne holdings.”
Bio-Techne - September 2025
“Mairs & Power Growth Fund Contributors Largest relative contributors and detractors are securities that were selected based on their contribution to the portfolio as of September 30, 2025. The performance is based on total return of the security for the period and includes only securities held for the entire period. Total return is the amount of value an investor earns from a security over a specific period and when distributions are reinvested. nVent Electric PLC NVIDIA Corp. JPMorgan Chase & Co. Fastenal Company Microsoft Corp. Fiserv, Inc. UnitedHealth Group, Inc. Bio-Techne Corp. Workiva Inc. Class A Hormel Foods Corp.”
Bio-Techne - June 2025
“ Bio-Teche Corp. (TECH) is seeing some financial progress against stabilizing and hopefully improving end markets, but its life sciences and China exposure continued to be viewed as risks.”
Bio-Techne - June 2025
“TECH Bio-Techne Corporation Manufactures and sells biological products 1.50 -12.08 -0.29 AJG Arthur J. Gallagher & Co. Provides insurance brokerage and third-party claims settlement and administration services. 2.17 -7.09 -0.29 WST West Pharmaceutical Services, Inc. Manufactures and markets pharmaceuticals, biologics, vaccines & consumer healthcare products 3.96 -2.12 -0.22 PINS Pinterest, Inc. Class A Operates a pinboard-style photo-sharing website 0.15 -0.82 -0.17 ENTG Entegris, Inc. Manufactures and supplies critical materials for the semiconductor, data storage & pharmaceutical industries 0.62 -9.28 -0.16 Bio-Techne shares fell—alongside most other life science tools companies—after the announcement of steep proposed cuts to the NIH budget.”
Bio-Techne - June 2025
“Bio-Techne Bio-Techne detracted from relative performance in the second quarter, as investor concerns rose for companies in the life sciences and tools industry with outsized exposure to the academic and government sectors.”
Bio-Techne
Fund coverage · 3 theses
- Clearbridge Mid Cap StrategySeptember 2025
Bio-Techne is a high-quality growth-oriented compounder in health care, providing durable recurring revenue streams through its life sciences tools and diagnostics.
Read the full thesis - Headwaters CapitalJune 2025
Bio-Techne (TECH) is a leading life sciences reagents and instruments company with strong recurring revenue, a healthy cash position, and potential for higher growth, despite current valuation pressures due to concerns over academic funding.
Read the full thesis - Polen US Small Company GrowthMarch 2025
Bio-Techne is a leading provider of life sciences tools with strong long-term growth potential driven by innovation and exposure to emerging markets like cell and gene therapy.
Read the full thesis
Read every full thesis on Bio-Techne
Read all 3 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→